Finding new drugs to fight drug-resistant infections
Discovery of Hsp100-selective inhibitors for targeting multiple microbial pathogens
This study is looking for new medicines that can help fight infections caused by tough bacteria like Shigella and E. coli by blocking a special protein that helps these germs survive, which could lead to better treatments for people with drug-resistant infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kansas State University NIH-funded |
| Lab location | 1 site (Manhattan, United States) |
| Project ID | NIH-10440373 on NIH RePORTER |
What this research studies
This research focuses on discovering small-molecule inhibitors that target Hsp100 chaperones, which are crucial for the survival and virulence of various pathogenic microorganisms. By using high-throughput screening of chemical libraries, the researchers aim to identify compounds that can inhibit the function of these chaperones, particularly in bacteria like Shigella and E. coli. The study seeks to develop new antimicrobial agents that can effectively combat infections caused by drug-resistant strains, ultimately improving treatment options for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by drug-resistant bacteria.
Not a fit: Patients with infections that are not caused by microbial pathogens or those who are not affected by antibiotic resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antibiotics that are effective against drug-resistant infections.
How similar studies have performed: Other research has shown promise in targeting molecular chaperones for antimicrobial development, indicating that this approach has potential for success.
Where this research is happening
Manhattan, United States
- Kansas State University — Manhattan, United States (Active)
Researchers
- Principal investigator: Zolkiewski, Michal — Kansas State University
- Study coordinator: Zolkiewski, Michal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.